CN105412155B - Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer - Google Patents
Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer Download PDFInfo
- Publication number
- CN105412155B CN105412155B CN201510890388.1A CN201510890388A CN105412155B CN 105412155 B CN105412155 B CN 105412155B CN 201510890388 A CN201510890388 A CN 201510890388A CN 105412155 B CN105412155 B CN 105412155B
- Authority
- CN
- China
- Prior art keywords
- colon cancer
- mouse
- group
- application
- eps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application of colon cancer and its application of combination chemotherapeutic drug therapy colon cancer are treated and prevented the invention discloses trichoderma pseudokoningii exocellular polysaccharide.Trichoderma pseudokoningii exocellular polysaccharide (EPS) can obviously inhibit the growth of the tumor mass of colon cancer tumours mouse, interleukin 2 (IL-2) in mouse immune shoot formation and mice serum, tumor necrosis factor-alpha (TNF-α) level are improved, mouse cytotoxic T lymphocyte (CD8 is improved+T cell) the total T lymphocyte of Zhan ratio, it is significant to activate mouse T lymphocyte and bone-marrow-derived lymphocyte, have the function for the treatment of colon cancer；Preventative intake EPS can also effectively improve the antitumor ability of body.And the antitumous effect of independent 5-FU medication is apparently higher than with existing chemotherapeutics 5 FU 5 fluorouracil (5-FU) drug combination antitumor curative effect.Furthermore, it is possible to improve colon cancer mouse survival quality, extend its service life.
Description
Technical field
The invention belongs to field of medicaments, and in particular to the application of trichoderma pseudokoningii exocellular polysaccharide treatment and prevention colon cancer,
And its application of combination chemotherapeutic drug therapy colon cancer.
Background technique
Cancer is well-known the serious disease for seriously endangering human life and health and threatening human social development.With
Today's society human habitat increasingly pollute, the raising of people's lives pressure, aging of population and people's lives are daily
Eating habit variation etc. causes the death rate of cancer to increase.Tumor in digestive tract is worldwide common cancer, mainly
Including gastric cancer, the cancer of the esophagus, colorectal cancer and liver cancer etc..
In the U.S., colorectal cancer arranged third position in cancer morbidity and the death rate, at 2014 about 71830
Male and 65000 women will be diagnosed as colorectal cancer, and will have 26270 males and 24040 women that will die of this
Kind malignant disease, and China has become tumor in digestive tract hotspot, morbidity and mortality are always situated in malignant tumour
Forefront.
Chemotherapeutics is the conventional medicament for treating tumour, and clinically most chemotherapeutics is thin in killing tumour at present
Also body normal cell is killed while born of the same parents, lacks targeting, very major injury is caused to hemopoietic system, immune system etc..
Natural polysaccharide has the multiple biological activities such as antitumor, immunological regulation, antiviral, anti-oxidant, anti-radiation and toxicity
It is very low, become one of the important sources of exploitation cancer treatment drugs.Start the end of the fifties it is found that polysaccharide has anti-swell
After tumor activity, the research of polysaccharide pharmacological action is gradually had developed.Immunological regulation is the most important biological activity of polysaccharide.
Studies have shown that immunoregulation effect of the polysaccharide to body, including activating macrophage, activation B cell and T cell, activating complement,
The formation for promoting interferon, promotes the formation of interleukins, induced tumors necrosin inhibits the effect etc. of tumour.
Natural animal and plant polyose with anti-tumor activity are widely present in nature, and are developed into one
Kind new type antineoplastic medicine will often be obtained using developing and consuming other natural resources as cost.Many studies have shown that mould
The polysaccharide in source similarly has various biological activity, because environment needed for low in cost, growth needed for its exploitation is simple, consumption
The advantages such as resource is few, culture is easy to operate and be concerned.Since Japanese scholars report lentinan in 1969 has antitumor work
Property after, native fungal polysaccharide increasingly by the extensive concern of domestic and foreign scholars, later again have about more than 200 kinds have it is antitumor
Active fungi polysaccharide is found successively, and China's fungus resource is abundant, obtains very big progress in recent years to the research of fungi polysaccharide.
Culture presevation number is trichoderma pseudokiningii (Trichoderma pseudokoningii) fungi of CGMCC No.1443
It is to separate to obtain from corn stover, there is very strong growth vigor, is secreted during liquid fermentation and culture a large amount of extracellular
Polysaccharide.It is extracellular that Chinese patent literature CN101220101A (application No. is 200810014047.8) discloses a kind of trichoderma pseudokiningii
Polysaccharide, the polysaccharide are characterized in that: (1) being detected by efficient gel filtration chromatography, with single symmetrical peak, molecular weight is
18325；(2) by the sulfuric acid-phynol method of improvement and phenyl phynol method detection, neutral polyoses content is 65.2%, alditol
Acid content is 32.6%；(3) it is analyzed by the GC of alditol acetate, monosaccharide group becomes rhamnose, glucose and galactolipin, rubs
You are than being RHA:GLC:GAL=5.6:2.7:1.0.After the polysaccharide restores completely, the molar ratio of rhamnose, glucose and galactolipin
For RHA:GLC:GAL=14.5:9.3:1.0, and it contains the glucuronic acid that molar content is 26.6%.This quasi- Kang Shi
The preparation method of trichoderma exocellular polysaccharide includes the preparation of Thick many candies and the purifying of polysaccharide.
Currently, the functional study of trichoderma pseudokoningii exocellular polysaccharide has become the hot spot of trichoderma pseudokiningii bacterium research, but should
There is not been reported to solid tumor resisting, the especially research of inhibitor against colon carcinoma cells tumor promotion for polysaccharide.
Summary of the invention
The contents of the present invention are trichoderma pseudokoningii exocellular polysaccharide as the application and quasi- Kang Shi for treating and preventing colon cancer
The application of trichoderma exocellular polysaccharide combined chemotherapy drug therapy colon cancer.
The trichoderma pseudokiningii is the trichoderma pseudokiningii (Trichoderma of CGMCC No.1443
pseudokoningii)。
The mechanism for inhibiting colon cancer tumours growth in the trichoderma pseudokoningii exocellular polysaccharide body is small by improving tumour
Mouse function of immune system achievees the effect that antitumor: after gastric infusion, IL-2 in mouse immune shoot formation and mice serum,
TNF-α level is significantly improved, mouse CD8+The ratio of the total T lymphocyte of T cell Zhan gets a promotion, while quasi- Kang Shi wood
Mould exocellular polysaccharide significantly activates mouse T lymphocyte and bone-marrow-derived lymphocyte.
Compared with prior art, the present invention the trichoderma pseudokoningii exocellular polysaccharide can inhibit colon cancer tumours in vivo
Growth, improve mouse immune organ index and lymphokine IL-2 be horizontal, maintain and promote mouse CD8+T lymphocyte increases
It grows；It is horizontal to improve lymphokine TNF-α, killing tumor cell participates in immunological regulation；Activate mouse T lymphocyte and B lymph
Cell promotes mouse immunity of organisms, to achieve the purpose that antitumor in vivo.And combines with existing chemotherapeutics 5-FU and use
Medicine antitumor curative effect is apparently higher than the antitumous effect of independent 5-FU medication, while being obviously improved mouse survival quality, to the heart,
Liver, kidney have certain protective effect.In addition in Life extending experiments, the colon cancer of trichoderma pseudokoningii exocellular polysaccharide administration
Bearing Mice Life has obtained significant extension.
Figure of description
Fig. 1 is inhibiting effect of the trichoderma pseudokoningii exocellular polysaccharide EPS therapeutic administratp approach to CT26 tumor-bearing mice solid tumor；
Fig. 2 is inhibiting effect of the trichoderma pseudokoningii exocellular polysaccharide EPS prevention administration approach to CT26 tumor-bearing mice solid tumor；
Fig. 3 A is the shadow under trichoderma pseudokoningii exocellular polysaccharide EPS therapeutic administratp approach to CT26 colon cancer mouse immune organ
It rings；
Fig. 3 B is the shadow under trichoderma pseudokoningii exocellular polysaccharide EPS prevention administration approach to CT26 colon cancer mouse immune organ
It rings；
Fig. 4 is influence of the trichoderma pseudokoningii exocellular polysaccharide EPS to cytokine levels in CT26 colon cancer mice serum；
Fig. 5 is trichoderma pseudokoningii exocellular polysaccharide EPS on the value-added influence of CT26 colon cancer mouse spleen lymphocyte；
Fig. 6 A is tumor model group to CT26 colon cancer mouse CD8+T lymphocyte ratio；
Fig. 6 B is trichoderma pseudokoningii exocellular polysaccharide EPS (50mg/kg) to CT26 colon cancer mouse CD8+T lymphocyte ratio
Influence；
Fig. 6 C is trichoderma pseudokoningii exocellular polysaccharide EPS (100mg/kg) to CT26 colon cancer mouse CD8+T lymphocyte ratio
The influence of example；
Fig. 6 D is trichoderma pseudokoningii exocellular polysaccharide EPS (200mg/kg) to CT26 colon cancer mouse CD8+T lymphocyte ratio
The influence of example；
Fig. 6 E is 5 FU 5 fluorouracil to CT26 colon cancer mouse CD8+The influence of T lymphocyte ratio；
Fig. 6 F is to CT26 colon cancer mouse CD8+The comparison of the influence of T lymphocyte ratio；
Wherein:
* after indicating that t is examined, it is in compared with tumor model group significant difference (P < 0.05)；
After * indicates that t is examined, it is in compared with tumor model group extremely significant sex differernce (P < 0.01)；
After * * indicates that t is examined, it is in compared with tumor model group extremely significant sex differernce (P < 0.001).
Specific embodiment
The present invention is further elaborated below with reference to embodiment, but institute's protection scope of the present invention is without being limited thereto.
In embodiment, trichoderma pseudokiningii (Trichoderma pseudokoningii) is purchased from China General Microbiological strain
Preservation administrative center, culture presevation number are CGMCC No.1443；
Trichoderma pseudokoningii exocellular polysaccharide is polysaccharide prepared by CN101220101A；
RPMI-1640 culture medium, fetal calf serum, it is dual anti-be purchased from Gibco company；
5 FU 5 fluorouracil, concanavalin A (ConA), lipopolysaccharides (LPS) are purchased from Sigma company；
CD3 and CD8a antibody is purchased from eBioscience company；
CT26.WT mouse colonic cell is purchased from Chinese Academy of Sciences's Institute of Cell Biology；
Other reagents be it is commonly used in the art commercially available, analyze it is pure；
BALB/C mice is purchased from Nanjing Qinglongshan cultivation base；
PBS: a kind of buffer is formulated by distilled water, and every liter contains: potassium dihydrogen phosphate 0.27g, disodium hydrogen phosphate
1.42g, sodium chloride 8g, potassium chloride 0.2g, pH7.4
Embodiment 1
Trichoderma pseudokoningii exocellular polysaccharide treatment and prevention administration act on colon cancer BALB/C mice Tumor growth inhibition
By being inoculated with CT26 colon cancer cell line to BALB/C mice, Transplanted Colon Cancer in Nude Mice model, treatment way are established
Diameter is tested using tumour, the administration of grouping in second day is first connect；EPS is detected to colon cancer tumours therapeutic effect
Prevention approach inoculates the approach that tumor strain continues to be administered using first gastric infusion and is tested, it is intended to detect EPS pairs
The effect of colon cancer tumours prevention.
Specific experiment method:
Experiment one week before buy 18-22g female BAl BIc/C mice in animal house raise (23 ± 2 DEG C of room temperature, humidity 50% ±
10%) the colon cancer CT26 cell of logarithmic phase, is collected, phosphate buffer (PBS) is diluted to 2 × 105A/mL.Aseptic condition
Under, the left oxter of mouse is inoculated with 0.2mL colon cancer CT26 cell suspending liquid, observes 3-5d, it is harder grain of rice size occur to oxter
Tubercle is as the successful standard of modeling.
Therapeutic administratp approach: BALB/C colon cancer Transplanted tumor model mouse is randomly divided into 5 groups, every group 7, starts administration and controls
Treat experiment.Experimental group is respectively as follows: tumor model group (physiological saline), trichoderma pseudokiningii low dose group (50mg/kg/d), intends Kang Shi
Trichoderma middle dose group (100mg/kg/d), trichoderma pseudokiningii high dose group (200mg/kg/d), 5-FU group (20mg/kg/d).Often
Its timing gastric infusion is primary, successive administration 14d.
After the last administration, it is deprived of food but not water for 24 hours, weighing takes blood and puts to death mouse.Strip the tumor tissues of tumor-bearing mice simultaneously
Weighing calculates tumour inhibiting rate, strips tumor-bearing mice immune organ (thymus gland and spleen) and weigh, Computation immunity shoot formation.
Tumour inhibiting rate=[tumor model group knurl weight (mg)-administration group knurl weight (mg)]/tumor model group knurl weight (mg) ×
100%；
Index and spleen index=spleen weight (mg)/end weight (g)
Thymus index=thymic weight (mg)/end weight (g)
After the last administration, the blood sample of all administration group mouse is centrifuged 15 minutes in 10000rpm, takes serum,
ELISA method measures the concentration of interleukin 2 (IL-2) and tumor necrosis factor (TNF-α) in each group mice serum.
After the last administration, it prepares mouse boosting cell suspension (method is same as above) to be placed in RPMI-1640 complete medium, be made
1×106The cell suspension of a/mL takes cell suspension to be added in 96 porocyte culture plates, and every 100 μ L of hole is divided into three groups, every group 6
A multiple holes, each group be separately added into configured 100 μ L concanavalin A (ConA, 5 μ g/mL) and lipopolysaccharides (LPS, 10 μ g/mL) or
RPMI-1640 culture medium, so that final volume is 200 μ L, by cell incubation in CO2MTT is added in every hole in 44h in incubator
10 μ L of solution continues to cultivate 4h, and every hole sucks supernatant, 150 μ L dimethyl sulfoxides (DMSO) is added then to dissolve first a ceremonial jade-ladle, used in libation, is placed in
After shaking table mixes 15min, every hole OD value is read in microplate reader 570nm wavelength.
After the last administration, the spleen of each group mouse is taken, spleen is torn under gnotobasis and is separated, is moderately ground with syringe
Spleen tissue is pressed, single splenocyte is filled into the sterile small beaker containing erythrocyte cracked liquid by nylon mesh, from
Cold RPMI-1640 complete medium is added in the heart, determines separation with flow cytometry with propidium iodide (PI)/RNA enzyme dyeing
Splenocyte vigor, then by 300 μ L concentration of vigor qualification be 5 × 105A/mL splenocyte and 1.5 μ L FITC are marked anti-
The anti-mouse CD8a antibody mixing of mouse CD3 antibody and 3.75 μ L PE label is placed in 4 DEG C of refrigerators 30 minutes, after incubation not
Labeled antibody is washed away with the 3mL PBS containing 0.05% Sodium azide, and the splenocyte of dye marker is resuspended in 200 μ L and contains
Loading CD8 in Flow cytometry splenocyte in the FACS buffer solution of 2% fetal calf serum and 0.05% Sodium azide+T cell
The total T lymphocyte ratio of Zhan.
Prevention administration approach: BALB/C colon cancer Transplanted tumor model mouse is randomly divided into 4 groups, wherein 3 groups of mouse, fill respectively
Basic, normal, high dosage trichoderma pseudokoningii exocellular polysaccharide solution (being 50,100,200mg/kg/d respectively) after stomach aseptic filtration, often
Secondary stomach-filling 0.5ml, the tumor model group then isometric sterile saline of stomach-filling.After successive administration 7d, polysaccharide processing group and
Tumor model group mouse is inoculated with tumor strain under right axillary, continues that 14d is administered, conventinal breeding after administration, is deprived of food but not water for 24 hours, claims
Weight, takes blood and puts to death mouse.The tumor tissues of tumor-bearing mice and weighing are stripped, tumour inhibiting rate is calculated, tumor-bearing mice is stripped and device is immunized
Official's (thymus gland and spleen) simultaneously weighs, Computation immunity shoot formation.
Tumour inhibiting rate, thymus index, index and spleen index calculation method are same as above.
The signs such as spirit, activity, diet, fur of animal are observed during treating daily.
The results showed that
Tumor model foundation starts, and mouse fur is smooth, and feed water inlet is normal, and flexibly, group difference is unobvious for reaction.
There is different degrees of difference between group in increase and drug treatment with tumor tissues；Tumor model group mouse is taken the photograph
Appetite is decreased obviously, apathetic, and activity is slow and hair turns to be yellow；5-FU administration group mouse physique cachexy, activity are trembled,
Hair is chaotic uneven；And EPS administration group mouse survival situation is obviously organized compared with other, and life quality is extracellular with trichoderma pseudokiningii
Polysaccharide dosage increases and improves.
By table 1 and Fig. 1 it is found that 5-FU group, the knurl weight of EPS high dose group mouse and tumor model group significant difference (P <
0.01, P < 0.001), illustrating EPS in vivo has preferable function of tumor inhibition, and 5-FU group weight is substantially reduced, and EPS gives
Medicine group mouse weight does not show obvious exception, and chemotherapeutics 5-FU is prompted to have extremely strong toxicity to body, EPS administration group it is small
Mouse weight is higher than 5-FU group and tumor model group mouse weight is close, illustrates EPS to body and nontoxicity.
Table 1EPS to CT26 colon cancer mouse weight, knurl weight and tumour inhibiting rate influence (n=7,)
Compared with tumor model group,**P < 0.01,***P<0.001
2 prevention approach of table administration in EPS to CT26 colon cancer mouse weight, knurl weight and tumour inhibiting rate influence (n=7,)
Compared with tumor model group, P < 0.01 * P < 0.05, * *
By table 2 and Fig. 2 it is found that in prevention administration approach, the middle and high dosage group knurl weight of polysaccharide is significantly lower than tumor model group
(P < 0.05, P < 0.01) illustrates that preventative intake EPS equally enhances the antitumor ability of body.
Such as Fig. 3 A it is found that 5-FU group index and spleen index and thymus index obviously (P < 0.001) low compared with tumor model group, in EPS
Dosage group index and spleen index is obviously high (P < 0.05) compared with tumor model group, and the thymus index of all EPS administration group mouse is above
Tumor model group especially becomes apparent (Fig. 3 B) what the mouse of prevention administration approach experiment embodied.
As shown in Figure 4, compared with tumor model group, the IL-2 and TNF-α level of 5-FU group are substantially reduced (P < 0.01), phase
Instead, the IL-2 of EPS group mice serum and TNF-α level are higher than tumor model group and are in dose dependent.
As shown in Figure 5, in the lymphocyte proliferation experiment that no mitosis stimulates, EPS administration group mice spleen lymph is thin
Born of the same parents' appreciation rate is apparently higher than tumor model group and in dose dependent (P < 0.001), in concanavalin A (ConA, 5 μ g/mL) or
Under lipopolysaccharides (LPS, 10 μ g/mL) stimulation, the splenic lymphocytes appreciation rate of EPS group mouse obviously compared with tumor model group height (P <
0.01), but 5-FU group lymphocyte proliferation rate significantly reduces (P < 0.05).
Such as Fig. 6 A- Fig. 6 F it is found that EPS administration has been obviously improved mouse CD8+The ratio of the total T lymphocyte of T cell Zhan is simultaneously in
Dose dependent, and 5-FU administration reduces CD8+The ratio of T cell.
Embodiment 2
EPS combines 5 FU 5 fluorouracil to Transplanted Colon Cancer in Nude Mice growth inhibition effect
By being inoculated with colon cancer cell line to BALB/C mice, colon cancer mice-transplanted tumor model is established, using stomach-filling side
Method treats colon cancer mouse, observes effect of the EPS combined chemotherapy drug 5-FU to colon cancer tumor-bearing mice.
Experimental method:
Colon cancer transplantable tumor mouse model is established, method is the same as case study on implementation 1.
45 successful female BAl BIc/C mice mean randoms of modeling are divided into tumor model group (control group), 5-FU group
(20mg/kg/d), the basic, normal, high dosage combinations 5-FU group of EPS, difference dosage EPS 50mg/kg/d+5-FU 20mg/kg/d,
EPS 100mg/kg/d+5-FU20mg/kg/d,EPS 200mg/kg/d+5-FU 20mg/kg/d.Daily set time stomach-filling is given
Medicine is primary, and successive administration 10 days.It is deprived of food but not water 12h after the last administration, weighs, takes off neck and puts to death, 75% alcohol impregnates, and cuts off it
Tumor tissues and thymus gland spleen are removed in armpit skin and thoracic cavity, respectively weighing record.Calculate tumour inhibiting rate, index and spleen index and thymus gland
Index.
Tumour inhibiting rate=[(tumor model group average knurl weight-administration group average knurl weight)/tumor model group average knurl weight] ×
100%
Index and spleen index=spleen weight (mg)/end weight (g)
Thymus index=thymic weight (mg)/end weight (g)
After the last administration, it weighs and de- neck is put to death, 75% alcohol impregnates, and cuts off its thoracic cavity, removing heart, liver and its kidney
Dirty, weighing records respectively.
The results showed that
This research finds in the daily observation treated to mouse tumor, the mouse posture day of simple stomach-filling 5-FU administration group
Gradually thin and weak, hair color jaundice is matt and in disorder, and action and delay of response are drowsiness, and administering drug combinations group mouse survival state is obvious
Preferably, posture is plentiful compared with 5-FU administration group, and hair color is naturally submissive, takes action and is swift in response, and illustrates that EPS mitigates to a certain extent
Body bring neurotoxic injury is given in 5-FU treatment tumour, improves mouse survival quality
3 drug combination of table to CT26 colon cancer mouse weight, knurl weight and tumour inhibiting rate influence (n=7,)
Compared with tumor model group,*P < 0.05,**P < 0.01,***P < 0.001；Compared with 5-FU group,#P < 0.05,##
P < 0.01,***P < 0.001
The results are shown in Table 3 compares with tumor model group, and each medication group average mice body weight is decreased obviously, wherein 5-
The decline of FU group is the most obvious, illustrates independent 5-FU medicine toxicity maximum；But it is compared with 5-FU group, each drug combination group mouse is average
Weight obviously rises.Experimental result is also shown, and 5-FU group and drug combination group can significantly reduce the knurl weight of CT26 mouse, and
It is compared with 5-FU group, the knurl weight of the middle and high dosage group of drug combination is obviously more lower than 5-FU group, and is in dose dependent, wherein
EPS high dose (200mg/kg/d) joint 5-FU (20mg/kg/d) group knurl weight is minimum (P < 0.001), and tumour inhibiting rate highest reaches
72.24%, illustrate that EPS joint 5-FU medication has better curative effect to CT26 colon cancer.
Table 4 shows that compared with tumor model group, the thymus gland and spleen weight of each medication group are substantially reduced, but and 5-FU
Group is compared, and the thymus gland and spleen weight of each medication group rise, and illustrates that the intake of EPS improves the immune organ weight of mouse body
Amount, improves mouse immune index, enhances the immunity of mouse body.
4 drug combination of table to CT26 colon cancer mouse immune organ influence (n=7,)
Compared with tumor model group,*P < 0.05,**P < 0.01,***P<0.001；Compared with 5-FU group,#P < 0.05,##P<
0.01
It is compared as shown in table 5 with tumor model group, the organ weights of each medication group decline, wherein 5-FU liver weight
Decline significant (P < 0.01), kidney weight declines more significant (P < 0.001), prompt 5-FU to CT26 colon cancer mouse liver and
Toxicity of Kidney is maximum；It is compared with 5-FU group, each drug combination group organ weights are above 5-FU group, although no difference of science of statistics,
But illustrates that EPS can alleviate 5-FU to body heart, liver and kidney bring toxicity to a certain extent, have to these internal organs
There is certain protective effect.
5 drug combination of table to mouse heart, liver, kidney influence (n=7,)
Compared with tumor model group,*P < 0.05,**P < 0.01,***P<0.001
Embodiment 3
Trichoderma pseudokoningii exocellular polysaccharide, which extends CT26 colon cancer survival time of mice, tests
By establishing CT26 colon cancer mouse model, trichoderma pseudokoningii exocellular polysaccharide EPS is observed in 100mg/kg/d
The influence of dosage and its joint 5-FU medication to CT26 tumor-bearing mice life cycle,
Experimental method:
Colon cancer transplantable tumor mouse model is established, method is the same as embodiment 1.Mouse is randomly divided into 4 groups, every group 7, i.e. mould
Type control group (physiological saline), polysaccharide processing group (100mg/kg/dEPS), 5-FU group (20mg/kg/d), drug combination group
(100mg/kg/d EPS+20mg/kg/d5-FU), gastric infusion.It is inoculated with the administration of the 2nd day beginning set time, once a day, altogether
10d.It observes after drug withdrawal to dead mouse.When observing the mouse state of mind, activity, diet, hair etc., and recording mouse survival
Between.
The results showed that
Trichoderma pseudokoningii exocellular polysaccharide vivo medicine-feeding obtained, in inoculation the 4th day, each group mouse started tumour obviously occur
Fritter, model control group mouse tumor block formation speed are significantly faster than that EPS (100mg/kg/d) administration group and its joint 5-FU are used
Medicine group.Model control group reaction of animals is slow in experimentation, and diet is reduced.After being inoculated with the 7th day, each experimental mice difference journey
The appearance hair color of degree owes gloss, and hair trembles, rolls up and unite, reduction etc. of looking for food.Trichoderma pseudokoningii exocellular polysaccharide administration group, and its
Joint 5-FU medication group ordinary circumstance is better than model group and 5-FU group.
Increase in life span=[(administration group mean survival time-model control group mean survival time)/model control group is flat
Equal life span] × 100%
It the results are shown in Table 6, according to calculation formula, the polysaccharide administration group CT26 colon cancer mouse survival time is (42.1 ± 1.2)
It, increase in life span 131.31% has statistical significance (P < 0.01) compared with model control group, compared with 5-FU group,
With statistical significance (P < 0.05)；EPS joint 5-FU medication group equally extends the CT26 colon cancer mouse survival time, and life prolongs
Long rate is 97.25%, compared with model control group, is had statistical significance (P < 0.05).
Table 6EPS to CT26 colon cancer survival time of mice influence (n=7,)
Compared with model control group, P < 0.01 * P < 0.05, * *, compared with 5-FU group,#P<0.05
Available from above data, trichoderma pseudokoningii exocellular polysaccharide has the function of preventing and treating colon cancer, and
The colon cancer mouse survival time can be extended.
Claims (3)
1. application of the trichoderma pseudokoningii exocellular polysaccharide in preparation treatment colon cancer drug.
2. trichoderma pseudokoningii exocellular polysaccharide is preparing the application in the drug that prevents colon cancer.
3. trichoderma pseudokoningii exocellular polysaccharide combines application of the 5 FU 5 fluorouracil in preparation treatment colon cancer drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510890388.1A CN105412155B (en) | 2015-12-02 | 2015-12-02 | Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510890388.1A CN105412155B (en) | 2015-12-02 | 2015-12-02 | Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105412155A CN105412155A (en) | 2016-03-23 |
| CN105412155B true CN105412155B (en) | 2019-03-12 |
Family
ID=55491004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510890388.1A Active CN105412155B (en) | 2015-12-02 | 2015-12-02 | Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105412155B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113367160B (en) * | 2021-06-09 | 2022-07-01 | 云南星耀生物制品有限公司 | Application of trichoderma viride preparation in preventing and treating tomato gray mold |
| CN115634232A (en) * | 2022-08-05 | 2023-01-24 | 郑州大学第一附属医院 | Application of Weissella fusion J4-1 extracellular polysaccharide in resisting colorectal cancer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001292790A (en) * | 2000-04-11 | 2001-10-23 | Daicel Chem Ind Ltd | Method for producing new 4-halogenated-3- hydroxybutyric acid ester |
| CN1867252A (en) * | 2003-09-08 | 2006-11-22 | 普罗医药公司 | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| CN101220101A (en) * | 2008-01-23 | 2008-07-16 | 山东大学 | Trichoderma pseudokoningii exocellular polysaccharide, preparation method and application thereof |
-
2015
- 2015-12-02 CN CN201510890388.1A patent/CN105412155B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001292790A (en) * | 2000-04-11 | 2001-10-23 | Daicel Chem Ind Ltd | Method for producing new 4-halogenated-3- hydroxybutyric acid ester |
| CN1867252A (en) * | 2003-09-08 | 2006-11-22 | 普罗医药公司 | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| CN101220101A (en) * | 2008-01-23 | 2008-07-16 | 山东大学 | Trichoderma pseudokoningii exocellular polysaccharide, preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 拟康氏木霉胞外多糖对小鼠的免疫增强活性研究;孔梦丽;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20120415(第4期);第E057-486页，尤其是第Ⅰ-Ⅱ页摘要 |
| 拟康氏木霉胞外总多糖免疫活性研究;李丽华等;《赤峰学院学报（自然科学版）》;20130430;第29卷(第4期);第22-23页 |
| 黑灵芝多糖的抗肿瘤活性及其分子机制初探;张莘莘;《中国博士学位论文全文数据库 工程科技Ⅰ辑》;20141115(第11期);第B016-9页，尤其是第120页第2-3段 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105412155A (en) | 2016-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10092592B2 (en) | Application of cyclic dinucleotide (cGAMP) in anti-tumor field | |
| Namba | Maitake D-fraction: healing and preventive potential for cancer | |
| RU2153332C2 (en) | Method of sensitization of cancer cells to lysis mediated by killer-cells | |
| CN1946392B (en) | Use of acethyldiacylglycerole derivatives in preparing autoimmune agents and health food | |
| CN102215837A (en) | Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor | |
| CN104146248B (en) | A kind of immunity nourishment composition and application thereof | |
| CN102526445A (en) | Health-care medicament formula with functions of strengthening immunity, relieving physical fatigue and resisting tumor | |
| CN101805763A (en) | Inonotus obliquus extracellular and intracellular mixing crude polysaccharide with function of strengthening immunity | |
| CN107613997A (en) | The extract rich in vitamin D and its composition of edible fungus and their applications in the immune related disorder for the treatment of | |
| CN105412155B (en) | Trichoderma pseudokoningii exocellular polysaccharide treats and prevents the application of colon cancer and its is combined the application of chemotherapeutic drug therapy colon cancer | |
| CN104042623A (en) | Application of rhizopus nigricans exopolysaccharides in preparation of medicine for treating or preventing gastrointestinal tumors | |
| CN115414390B (en) | Probiotic composite preparation with intestinal microecology improving and tumor immune checkpoint inhibitor treatment effect enhancing effects and application | |
| Konno | Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy | |
| Kodama et al. | Potential antitumor activity of a low-molecular-weight protein fraction from Grifola frondosa through enhancement of cytokine production | |
| CN104857018B (en) | Raspberry polysaccharide prepares the purposes of antineoplastic combination medication with chemotherapeutics | |
| CN102212505B (en) | Immune killer cell, preparation method thereof, medicinal composition containing immune killer cell and set | |
| US20120003262A1 (en) | Anticancer health food containing phellinus linteus and vegetable worms | |
| CN111450124A (en) | Application of Achimbe or prevotella in medicine for increasing tumor microenvironment gamma T cell accumulation and enhancing anti-tumor immune function | |
| CN108721313A (en) | A kind of Vitamin D receptor agonist | |
| CN113244246B (en) | Application of microbial plasmalogen in treatment of colon cancer | |
| CN100544736C (en) | A kind of pharmaceutical composition of enhancing immunity and preparation method | |
| JP4308350B2 (en) | LAK activity screening substance containing shiitake mycelium extract and LAK activity screening method using the same | |
| CN105012366B (en) | A kind of bright moon grass polysaccharide and its application in preparing for immunological regulation and anti-tumor drug and functional food | |
| CN101850110A (en) | Novel medicinal composition and preparation method | |
| CN114642675B (en) | Application of L-sorbose in preparing medicine for treating tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |